266 related articles for article (PubMed ID: 34518534)
21. Zinc finger protein 382 is downregulated by promoter hypermethylation in pediatric acute myeloid leukemia patients.
Tao YF; Hu SY; Lu J; Cao L; Zhao WL; Xiao PF; Xu LX; Li ZH; Wang NN; Du XJ; Sun LC; Zhao H; Fang F; Su GH; Li YH; Li YP; Xu YY; Ni J; Wang J; Feng X; Pan J
Int J Mol Med; 2014 Dec; 34(6):1505-15. PubMed ID: 25319049
[TBL] [Abstract][Full Text] [Related]
22. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia.
Mardiros A; Dos Santos C; McDonald T; Brown CE; Wang X; Budde LE; Hoffman L; Aguilar B; Chang WC; Bretzlaff W; Chang B; Jonnalagadda M; Starr R; Ostberg JR; Jensen MC; Bhatia R; Forman SJ
Blood; 2013 Oct; 122(18):3138-48. PubMed ID: 24030378
[TBL] [Abstract][Full Text] [Related]
23. Targeting transcription factor SALL4 in acute myeloid leukemia by interrupting its interaction with an epigenetic complex.
Gao C; Dimitrov T; Yong KJ; Tatetsu H; Jeong HW; Luo HR; Bradner JE; Tenen DG; Chai L
Blood; 2013 Feb; 121(8):1413-21. PubMed ID: 23287862
[TBL] [Abstract][Full Text] [Related]
24. Regulation of glutamine carrier proteins by RNF5 determines breast cancer response to ER stress-inducing chemotherapies.
Jeon YJ; Khelifa S; Ratnikov B; Scott DA; Feng Y; Parisi F; Ruller C; Lau E; Kim H; Brill LM; Jiang T; Rimm DL; Cardiff RD; Mills GB; Smith JW; Osterman AL; Kluger Y; Ronai ZA
Cancer Cell; 2015 Mar; 27(3):354-69. PubMed ID: 25759021
[TBL] [Abstract][Full Text] [Related]
25. MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cells.
Zeng Z; Wang RY; Qiu YH; Mak DH; Coombes K; Yoo SY; Zhang Q; Jessen K; Liu Y; Rommel C; Fruman DA; Kantarjian HM; Kornblau SM; Andreeff M; Konopleva M
Oncotarget; 2016 Aug; 7(34):55083-55097. PubMed ID: 27391151
[TBL] [Abstract][Full Text] [Related]
26. Novel, gel-free proteomics approach identifies RNF5 and JAMP as modulators of GPCR stability.
Roy SJ; Glazkova I; Fréchette L; Iorio-Morin C; Binda C; Pétrin D; Trieu P; Robitaille M; Angers S; Hébert TE; Parent JL
Mol Endocrinol; 2013 Aug; 27(8):1245-66. PubMed ID: 23798571
[TBL] [Abstract][Full Text] [Related]
27. The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR.
Zhou L; Chen S; Zhang Y; Kmieciak M; Leng Y; Li L; Lin H; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Rahmani M; Povirk L; Chalasani S; Berger AJ; Dai Y; Grant S
Blood; 2016 May; 127(18):2219-30. PubMed ID: 26851293
[TBL] [Abstract][Full Text] [Related]
28. CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells.
Surka C; Jin L; Mbong N; Lu CC; Jang IS; Rychak E; Mendy D; Clayton T; Tindall E; Hsu C; Fontanillo C; Tran E; Contreras A; Ng SWK; Matyskiela M; Wang K; Chamberlain P; Cathers B; Carmichael J; Hansen J; Wang JCY; Minden MD; Fan J; Pierce DW; Pourdehnad M; Rolfe M; Lopez-Girona A; Dick JE; Lu G
Blood; 2021 Feb; 137(5):661-677. PubMed ID: 33197925
[TBL] [Abstract][Full Text] [Related]
29. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
Fiskus W; Pranpat M; Balasis M; Herger B; Rao R; Chinnaiyan A; Atadja P; Bhalla K
Mol Cancer Ther; 2006 Dec; 5(12):3096-104. PubMed ID: 17172412
[TBL] [Abstract][Full Text] [Related]
30. CARM1 Is Essential for Myeloid Leukemogenesis but Dispensable for Normal Hematopoiesis.
Greenblatt SM; Man N; Hamard PJ; Asai T; Karl D; Martinez C; Bilbao D; Stathias V; Jermakowicz AM; Duffort S; Tadi M; Blumenthal E; Newman S; Vu L; Xu Y; Liu F; Schurer SC; McCabe MT; Kruger RG; Xu M; Yang FC; Tenen DG; Watts J; Vega F; Nimer SD
Cancer Cell; 2018 Jun; 33(6):1111-1127.e5. PubMed ID: 29894694
[TBL] [Abstract][Full Text] [Related]
31. Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes.
Hauswald S; Duque-Afonso J; Wagner MM; Schertl FM; Lübbert M; Peschel C; Keller U; Licht T
Clin Cancer Res; 2009 Jun; 15(11):3705-15. PubMed ID: 19458058
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive analysis of cytoskeleton regulatory genes identifies ezrin as a prognostic marker and molecular target in acute myeloid leukemia.
Lipreri da Silva JC; Coelho-Silva JL; Lima K; Vicari HP; Lazarini M; Costa-Lotufo LV; Traina F; Machado-Neto JA
Cell Oncol (Dordr); 2021 Oct; 44(5):1105-1117. PubMed ID: 34196912
[TBL] [Abstract][Full Text] [Related]
33. Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells.
Fiskus W; Rao R; Fernandez P; Herger B; Yang Y; Chen J; Kolhe R; Mandawat A; Wang Y; Joshi R; Eaton K; Lee P; Atadja P; Peiper S; Bhalla K
Blood; 2008 Oct; 112(7):2896-905. PubMed ID: 18660379
[TBL] [Abstract][Full Text] [Related]
34. Histone deacetylase inhibitor targets CD123/CD47-positive cells and reverse chemoresistance phenotype in acute myeloid leukemia.
Yan B; Chen Q; Shimada K; Tang M; Li H; Gurumurthy A; Khoury JD; Xu B; Huang S; Qiu Y
Leukemia; 2019 Apr; 33(4):931-944. PubMed ID: 30291336
[TBL] [Abstract][Full Text] [Related]
35. Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia.
Li X; Su Y; Madlambayan G; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Ma J; Knight T; Wang G; Wang Y; Yang J; Taub JW; Lin H; Ge Y
Haematologica; 2019 Nov; 104(11):2225-2240. PubMed ID: 30819918
[TBL] [Abstract][Full Text] [Related]
36. The impact of biology on the treatment of secondary AML.
Gojo I; Karp JE
Cancer Treat Res; 2001; 108():231-55. PubMed ID: 11702601
[No Abstract] [Full Text] [Related]
37. FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia.
Long J; Jia MY; Fang WY; Chen XJ; Mu LL; Wang ZY; Shen Y; Xiang RF; Wang LN; Wang L; Jiang CH; Jiang JL; Zhang WJ; Sun YD; Chang L; Gao WH; Wang Y; Li JM; Hong DL; Liang AB; Hu J
Blood; 2020 Apr; 135(17):1472-1483. PubMed ID: 32315388
[TBL] [Abstract][Full Text] [Related]
38. Rheb1 promotes tumor progression through mTORC1 in MLL-AF9-initiated murine acute myeloid leukemia.
Gao Y; Gao J; Li M; Zheng Y; Wang Y; Zhang H; Wang W; Chu Y; Wang X; Xu M; Cheng T; Ju Z; Yuan W
J Hematol Oncol; 2016 Apr; 9():36. PubMed ID: 27071307
[TBL] [Abstract][Full Text] [Related]
39. A small-molecule inhibitor and degrader of the RNF5 ubiquitin ligase.
Ruan J; Liang D; Yan W; Zhong Y; Talley DC; Rai G; Tao D; LeClair CA; Simeonov A; Zhang Y; Chen F; Quinney NL; Boyles SE; Cholon DM; Gentzsch M; Henderson MJ; Xue F; Fang S
Mol Biol Cell; 2022 Nov; 33(13):ar120. PubMed ID: 36074076
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of FLT3 and PIM Kinases by EC-70124 Exerts Potent Activity in Preclinical Models of Acute Myeloid Leukemia.
Puente-Moncada N; Costales P; Antolín I; Núñez LE; Oro P; Hermosilla MA; Pérez-Escuredo J; Ríos-Lombardía N; Sanchez-Sanchez AM; Luño E; Rodríguez C; Martín V; Morís F
Mol Cancer Ther; 2018 Mar; 17(3):614-624. PubMed ID: 29339551
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
